ProQR Therapeutics (PRQR) Total Non-Current Liabilities (2021 - 2024)
Historic Total Non-Current Liabilities for ProQR Therapeutics (PRQR) over the last 4 years, with Q4 2024 value amounting to $43.3 million.
- ProQR Therapeutics' Total Non-Current Liabilities fell 3543.17% to $43.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $43.3 million, marking a year-over-year decrease of 3543.17%. This contributed to the annual value of $43.8 million for FY2024, which is 3495.07% down from last year.
- ProQR Therapeutics' Total Non-Current Liabilities amounted to $43.3 million in Q4 2024, which was down 3543.17% from $67.0 million recorded in Q4 2023.
- In the past 5 years, ProQR Therapeutics' Total Non-Current Liabilities registered a high of $85.3 million during Q4 2022, and its lowest value of $43.3 million during Q4 2024.
- Over the past 4 years, ProQR Therapeutics' median Total Non-Current Liabilities value was $72.8 million (recorded in 2023), while the average stood at $68.6 million.
- In the last 5 years, ProQR Therapeutics' Total Non-Current Liabilities surged by 850.97% in 2022 and then crashed by 3543.17% in 2024.
- Quarter analysis of 4 years shows ProQR Therapeutics' Total Non-Current Liabilities stood at $78.7 million in 2021, then increased by 8.51% to $85.3 million in 2022, then decreased by 21.47% to $67.0 million in 2023, then tumbled by 35.43% to $43.3 million in 2024.
- Its Total Non-Current Liabilities stands at $43.3 million for Q4 2024, versus $67.0 million for Q4 2023 and $85.3 million for Q4 2022.